Search results
Results from the WOW.Com Content Network
Average number of moderate-to-severe hot flashes per week with placebo and different doses of oral estradiol in menopausal women [40] [41]. Estradiol is used in menopausal hormone therapy to prevent and treat moderate to severe menopausal symptoms such as hot flashes, vaginal dryness and atrophy, and osteoporosis (bone loss). [11]
Estrogen and other hormones are given to postmenopausal women in order to prevent osteoporosis as well as treat the symptoms of menopause such as hot flashes, vaginal dryness, urinary stress incontinence, chilly sensations, dizziness, fatigue, irritability, and sweating. Fractures of the spine, wrist, and hips decrease by 50 to 70% and spinal ...
HDE and/or pseudopregnancy have been used in clinical medicine for the following indications: Estrogen receptor-positive breast cancer in women [1] As a means of androgen deprivation therapy for prostate cancer and benign prostatic hyperplasia in men [7] [8] [10] In combination with progestins for endometriosis in women.
Osteoporosis affects more women than men. Of the estimated 10 million Americans with osteoporosis, more than 8 million (or 80%) are women. ... osteoporosis affects one in four women 65 or older ...
Estrogen can also reduce vaginal atrophy and increase sexual arousal, frequency and orgasm. [22] The effectiveness of hormone replacement can decline in some women after long-term use. [22] A number of studies have also found that the combined effects of estrogen/androgen replacement therapy can increase libido and arousal over estrogen alone. [22]
The total endometrial proliferation dose of sublingual estradiol in women is 60 to 140 mg per cycle or 14 days and of sublingual estradiol benzoate in women is 60 to 180 mg per cycle or 14 days. [75]: 310 Both sublingual estradiol and sublingual estradiol benzoate have a persistence of estrogenic effect after a dose of only one day.
Estradiol valerate is usually used in the treatment of advanced prostate cancer in men at a dosage of 30 mg or more every 1 to 2 weeks by intramuscular injection. [13] In transgender women, estradiol valerate given by intramuscular injection is usually used at a dosage of 5 to 20 mg, but up to 30 to 40 mg, once every 2 weeks.
Research shows men are more likely than women to avoid—or delay—necessary medical care, even when their symptoms disrupt their lives or become chronic. An online survey conducted by the ...